Jack Jones

Cooley advised Uber Technologies (NYSE: UBER), a technology platform that uses a massive network, leading technology, operational excellence and product expertise to power movement from point A to point B, on its $2.25 billion investment-grade bond offering.

Cooley advised Medicxi and other venture capital investors in Sanofi’s $1.6 billion acquisition of Vicebio, a biopharmaceutical company that develops novel vaccines against life-threatening respiratory viral infections.

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised PetLab Co., a rapidly growing independent pet supplement brand headquartered in London, on its majority stake sale to BC Partners, a top international investment firm.

Cooley advised GeBBS Healthcare Solutions, a global provider of healthcare outsourcing solutions, and ChrysCapital, a top India-focused private equity firm, on the agreement for BPEA Private Equity Fund VIII (EQT Private Capital Asia) to acquire a controlling beneficial interest in GeBBS from ChrysCapital.